Neuren presenting at Jefferies Global Healthcare Conference
Released
Released
Announcement PDF
Neuren (NEU) – ASX announcement
5 June 2023
Neuren presenting at Jefferies Global Healthcare Conference
Melbourne, Australia: Neuren Pharmaceuticals (ASX: NEU) CEO Jon Pilcher will present at the Jefferies
Global Healthcare Conference in New York on Thursday 8 June at 2:00pm EST (Friday 9 June at 4:00am
AEST).
The presentation is available to live-stream, with the link available on Neuren’s website
www.neurenpharma.com under Investors, Investor Presentations.
About Neuren
Neuren is developing new drug therapies to treat multiple serious neurological disorders that emerge in
early childhood and have no or limited approved treatment options.
DAYBUE™ (trofinetide) is approved by the US Food and Drug Administration (FDA) for the treatment of
Rett syndrome in adult and pediatric patients two years of age and older. Neuren has granted an
exclusive licence to Acadia Pharmaceuticals Inc. for the development and commercialisation of
trofinetide in North America, while retaining all rights outside North America.
Neuren is conducting Phase 2 trials of its second drug candidate, NNZ-2591, for each of PhelanMcDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome.
Recognising the urgent unmet need, all programs have been granted “orphan drug” designation in the
United States. Orphan drug designation provides incentives to encourage development of therapies for
rare and serious diseases.
Contact:
Jon Pilcher, CEO: jpilcher@neurenpharma.com; +61 438 422 271
ASX Listing Rules information
This announcement was authorized to be given to the ASX by the board of directors of Neuren
Pharmaceuticals Limited, Suite 201, 697 Burke Road, Camberwell, VIC 3124
Forward-looking Statements
This announcement contains forward-looking statements that are subject to risks and uncertainties. Such
statements involve known and unknown risks and important factors that may cause the actual results,
performance or achievements of Neuren to be materially different from the statements in this
announcement.
1 of 1
Share your feedback
Discover